NUVB News - Candlesense

Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today reported financial results for the second qu...

What are the risks of regulatory or manufacturing setbacks that could delay broader commercialization? How might this FDA approval impact Nuvation Bio's valuation multiples relative to peers? Will the company’s balance sheet and cash runway support the commercial launch without additional financing?

Earnings

18 days ago

Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that new data will be p...

What are the anticipated pricing and reimbursement scenarios for IBTROZI™ if it receives approval? What are the key risk factors (e.g., safety concerns, enrollment delays) that could affect investor confidence? How will the results affect the valuation of NUVB relative to its peers (e.g., Incyte, Merck, Bristol‑Myers Squibb) in the oncology space?

Clinical trials

20 days ago

U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and ...

Fda approval

2 months ago